OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

OCX has been the topic of a number of other reports. Benchmark reiterated a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research note on Monday. Stephens reissued an “equal weight” rating and set a $4.00 price objective on shares of OncoCyte in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.90.

OncoCyte Trading Down 5.8 %

Shares of OncoCyte stock opened at $2.59 on Thursday. OncoCyte has a 52-week low of $2.08 and a 52-week high of $6.80. The company’s 50-day simple moving average is $2.95 and its 200-day simple moving average is $3.06.

Insider Buying and Selling

In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of OncoCyte stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of OncoCyte stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Andrew Arno purchased 33,898 shares of OncoCyte stock in a transaction on Thursday, April 11th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the acquisition, the director now directly owns 69,054 shares of the company’s stock, valued at $203,709.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 2,457,288 shares of company stock valued at $7,176,400. Corporate insiders own 1.94% of the company’s stock.

Institutional Trading of OncoCyte

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. purchased a new position in shares of OncoCyte during the first quarter valued at approximately $25,000. DCF Advisers LLC lifted its stake in shares of OncoCyte by 107.0% during the first quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after buying an additional 13,000 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of OncoCyte during the second quarter valued at approximately $25,000. Balyasny Asset Management LLC lifted its stake in shares of OncoCyte by 389.9% during the third quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after buying an additional 42,091 shares during the period. Finally, LPL Financial LLC lifted its stake in shares of OncoCyte by 58.1% during the second quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after buying an additional 40,000 shares during the period. Hedge funds and other institutional investors own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.